Related Experiment Video
Updated: May 9, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Associations between interleukin-23R and interleukin-12B polymorphisms and psoriasis susceptibility: a meta-analysis
1Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine , Seoul , Korea.
Objective:
The aim of this study was to determine whether interleukin (IL)-23 R and IL-12B polymorphisms confer susceptibility to psoriasis.
Methods:
The authors conducted a meta-analysis on associations between the IL-23 R and IL-12B polymorphisms and psoriasis susceptibility.
Results:
A total of 14 comparison studies were included in this meta-analysis. The meta-analysis identified a significant association between psoriasis and 2 alleles of the rs11209026 and rs7530511 polymorphisms in Europeans (odds ratio [OR] = 0.624, 95% confidence interval [CI] = 0.565-0.697, p < 1.0 × 10(-8); OR = 0.804, 95% CI = 0.743-0.869, p = 3.0 × 10(-7), respectively). Meta-analysis of IL-12B showed a significant association between the 2 alleles of the rs6887695 and rs3212227 polymorphisms and the risk of developing psoriasis (OR = 0.710, 95% CI = 0.673-0.749, p < 1.0 × 10(-8); OR = 0.684, 95% CI = 0.639-0.731, p < 1.0 × 10(-8), respectively). Stratification by ethnicity identified an association between the rs6887695 and rs3212227 polymorphisms and psoriasis in Europeans.
Conclusions:
This meta-analysis showed that the IL-23 R (rs11209026 and rs7530511) polymorphisms are associated with psoriasis risk in Europeans and that the IL-12B (rs6887695 and rs3212227) polymorphisms are associated with susceptibility to psoriasis in Europeans.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease III: Crohn's Disease
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu